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Despite the availability of nonpharmacological approaches
and pharmacological therapies for hypertension, blood pres-
sure control rates are disappointing all over the world [1].
Among several considerations, hypertension is usually asso-
ciated with metabolic disorders, especially obesity, diabetes,
anddyslipidemia,whichmaycontributetoagreaterdifficulty
ofloweringbloodpressure.Infact,thesignificantassociation
between systemic hypertension and other cardiometabolic
risk factors is well recognized, such as an elevated body mass
index,waistcircumference,fastingglucose,triglycerides,and
a reduced HDL cholesterol, even not reaching criteria for
diagnosis of metabolic syndrome. Individually, each one of
these metabolic disorders is associated with adverse cardio-
vascular outcomes.
Th i ss p e c i a li s s u ep r e s e n t ss o m ep a p e r sr e l a t e dt ot h e s e
cardiometabolic risk factors and their involvement mainly in
prognosis and treatment of hypertensive patients. Firstly, a
very low diastolic blood pressure, with a threshold value of
70mmHg, was associated with increased all-cause mortality.
It has been discussed that blood pressure level is the most
important factor in cardiovascular risk evaluation even in
hypertensive subjects with important metabolic disorders.
The linear relationship between blood pressure and cardi-
ovascularmortalitystartingfrom115/75mmHgiswellknown
[2]. Nevertheless, cardiovascular events have also been ob-
served after insistent lowering of blood pressure, at least in
patientswithcoronaryarterydisease[3].
Sleep disorders have been increasingly studied in recent
years. Obstructive sleep apnea is related to cardiovascular
disease and metabolic dysfunction, but sleep duration is a
parameter not commonly considered in this association. In-
deed, short sleep duration has been previously associated
with an increased likelihood for hypertension [4]. In a pa-
perofthiscollection,interactionsofdeficientsleepwithrace/
ethnicitywere notedeven after adjustingto metabolicfactors
suchasbodymassindexanddiabetes.Thiswasaninteresting
finding considering that insulin resistance exacerbated by
renin angiotensin system (RAS) activation might be a mech-
anism involved in the link between sleep disorders and met-
abolic syndrome. The causal relationship of RAS and oxida-
tive stress with vascular inflammation was documented in
this special issue in a study with an experimental model of
metabolic syndrome. In this protocol, a RAS inhibitor and
an antioxidant agent were able to attenuate metabolic factors
and systolic blood pressure in spontaneously hypertensive
rats submitted to fructose administration.
Theinteractionbetweenhypertensionanddiabetesseems
to be the principal concern to the cardiovascular system. The
mechanisms that may increase cardiovascular risk in diabet-
ic hypertensive patients are not completely understood. Oxi-
dative stress and low-grade inflammation resulting in endo-
thelial dysfunction as the first process of atherosclerosis were
reviewed in this special issue. These factors may be also rele-
vant in patients with longer duration of type 1 diabetes.2 International Journal of Hypertension
In another paper, a cross-sectional study carried out in 20
Brazilian cities demonstrated that less than one quarter of
treated type 1 diabetic patients achieved the target values for
systolic and diastolic blood pressure. These data indicate that
a more aggressive approach of this population is extremely
n e c e s s a rya l s oi nd e v e l o p i n gc o u n t r i e s .
Nutritionalfactorsinvolvedinthetreatmentofhyperten-
sive subjects are also discussed in this special issue. Many
dietary components, especially sodium, potassium, calcium,
a n dm a g n e s i u m ,a r er e v i e w e db a s e do nt h ea v a i l a b l ee v i -
dence. Restriction of daily sodium intake is recommended
in several guidelines about hypertension. However, low salt
intake has resulted in cardiovascular mortality in some par-
ticular groups of patients including diabetic subjects [5]. Po-
tassium, calcium, and magnesium supplementations are not
indicated as a usual practice for hypertensive subjects, but
natural source of these micronutrients is the mainstay of
the Dietary Approaches to Stop Hypertension (DASH) plan.
Also, as a nonpharmacologicalapproach,two originalpapers
in this collection demonstrated the beneficial effects of dark
chocolate consumption on endothelial function in specific
populations: stage 1 hypertensive subjects with excess body
weight and younger hypertensive individuals with low car-
diovascularriskwhoalreadypresentendothelialdysfunction.
It has been reported that these favorable outcomes are asso-
ciated with reasonably high amount of polyphenol in dark
chocolate.
Lastly, in a study that enrolled patients with uncon-
trolled hypertension and criteria for metabolic syndrome,
moxonidinetherapyresultedinbloodpressurereductionand
improvement of blood pressure control rates, especially in
younger individuals. The pharmacological treatment of hy-
pertension in the context of metabolic syndrome presents
many challenges in the daily clinical practice due to several
mechanisms involved in this medical condition including
thesympatheticnervoussystem(SNS)hyperactivation.Thus,
moxonidine, a selective agonist at the imidazoline receptor
subtype 1 which determines a decrease in SNS activity, may
be beneficial in this circumstance.
Undoubtedly, hypertension is very commonly associated
with other metabolic chronic conditions. In fact, more than
80% of hypertensive patients present one or more concomi-
tantmetabolicriskfactors.Thisclinicalconditionhasagrow-
ing global prevalence, clearly related to the modern lifestyles
characterized by lack of physical activity resulting in over-
weight or obesity. Hopefully, we believe that this special issue
can help to better understand the interaction between raised
blood pressure levels and cardiometabolic factors, pointing
out the involvement of insulin resistance and RAS/SNS acti-
vationaslinkingfactorsandalsodiscussingsometherapeutic
options for this population.
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